Literature DB >> 11908247

Stability of irinotecan hydrochloride in aqueous solutions.

Wen Yen Li1, Robert T Koda.   

Abstract

The stability of irinotecan after reconstitution in several vehicles for i.v. infusion was studied. Irinotecan hydrochloride injection was diluted in phosphate buffer solution (pH 4.0, 6.0, and 7.4), 5% dextrose injection, and 0.9% sodium chloride injection to a final concentration of 20 micrograms/mL. The solutions were stored at 25, 37, and 50 degrees C and assayed at intervals up to 24 hours by high-performance liquid chromatography for the concentration of the lactone form of irinotecan remaining. The effect of temperature and pH on the extent and rate of degradation of irinotecan was determined. The hydrolysis of irinotecan to its carboxylate form was reversible. The rate and extent of hydrolysis increased with increasing pH. The use of a weakly acidic vehicle, such as 5% dextrose injection, for reconstitution of irinotecan may maintain the drug's stability prior to administration.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11908247     DOI: 10.1093/ajhp/59.6.539

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  5 in total

Review 1.  Stability of antineoplastic agents in use for home-based intravenous chemotherapy.

Authors:  Frédéric Benizri; Brigitte Bonan; Anne-Laure Ferrio; Marie-Laure Brandely; Vincent Castagné; Nathalie Théou-Anton; Muriel Verlinde-Carvalho; Laurent Havard
Journal:  Pharm World Sci       Date:  2008-12-10

2.  Role of Toll-like receptor 4 in drug-drug interaction between paclitaxel and irinotecan in vitro.

Authors:  Pankajini Mallick; Sumit Basu; Bhagavtula Moorthy; Romi Ghose
Journal:  Toxicol In Vitro       Date:  2017-02-27       Impact factor: 3.500

3.  Iontophoretic device delivery for the localized treatment of pancreatic ductal adenocarcinoma.

Authors:  James D Byrne; Mohammad R N Jajja; Allison N Schorzman; Amanda W Keeler; J Christopher Luft; William C Zamboni; Joseph M DeSimone; Jen Jen Yeh
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-08       Impact factor: 11.205

4.  The novel highly lipophilic topoisomerase I inhibitor DB67 is effective in the treatment of liver metastases of murine CT-26 colon carcinoma.

Authors:  Lluis A Lopez-Barcons; Junhong Zhang; Gunching Siriwitayawan; Thomas G Burke; Roman Perez-Soler
Journal:  Neoplasia       Date:  2004 Sep-Oct       Impact factor: 5.715

5.  A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients.

Authors:  G Allegrini; A Falcone; A Fioravanti; M T Barletta; P Orlandi; F Loupakis; E Cerri; G Masi; A Di Paolo; R S Kerbel; R Danesi; M Del Tacca; G Bocci
Journal:  Br J Cancer       Date:  2008-03-25       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.